# Pfizer Secures Up to $1.5 Billion From Blackstone to Fund Monthly Obesity Drug Through 2028

> Blackstone will provide up to $1.5 billion through 2028 to fund Pfizer's experimental monthly obesity treatment berobenatide, the company said.

- Published: 2026-11-11T22:25:35+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-11/pfizer-blackstone-obesity-drug-funding
- Source: [MarketScreener](https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623)

## Key takeaways

- Blackstone will provide up to $1.5 billion through 2028 to fund development of Pfizer's experimental monthly obesity treatment.
- The agreement is a strategic co-funding arrangement under which Blackstone pays up to $1.5 billion of berobenatide development costs through 2028.
- Pfizer acquired Metsera for approximately $10 billion in November 2025, gaining the obesity pipeline that includes berobenatide.

Pfizer said Blackstone will provide up to $1.5 billion through 2028 to help fund development of its experimental monthly obesity treatment, according to [MarketScreener](https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623). The announcement was made on November 11, 2026.

## How the Blackstone Co-Funding Works

[Pfizer](https://akta.pro/company-profiles/00000dw/pfizer) and [Blackstone](https://akta.pro/company-profiles/0000ggf/blackstone) announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion of development costs for berobenatide through 2028, Stock Titan reported. The funding is intended to support development of the drug, which Pfizer has described as a monthly obesity treatment.

Pfizer plans to launch its GLP-1 drug berobenatide in 2028, aiming to enter a market projected to reach $190 billion by 2035, The Motley Fool reported. The company cites its commercial execution strength, including scaling its COVID vaccine, as a key advantage.

Blackstone separately raised its takeover bid for IDP Education to A$833.7 million, offering A$3 per share at a 36% premium, MarketScreener reported. IDP's board is considering the revised offer, which follows two rejected bids.

## Pfizer's Obesity Pipeline and Deal History

Pfizer acquired Metsera for approximately $10 billion in November 2025 following a bidding war with Novo Nordisk, gaining access to an obesity drug pipeline including PF'3944 (berobenatide) and MET-097i for monthly dosing GLP-1 treatments, according to akta.pro [company records](https://akta.pro/company-data). The same records list a $6 billion post-IPO debt round in November 2025 and a $1 billion post-IPO equity round in October 2024 led by Starboard Value.

| Date | Round type | Amount | Lead investor |
| --- | --- | --- | --- |
| May 2023 | Post-IPO debt | $31 billion | Not stated |
| October 2024 | Post-IPO equity | $1 billion | Starboard Value |
| November 2025 | Post-IPO debt | $6 billion | Not stated |

## Earlier Pfizer Obesity Moves

Pfizer is advancing its GLP-1 weight-loss drugs through Phase 3 trials, aiming for a monthly shot option, with 10 late-stage trials, The Motley Fool reported in November 2026. Pfizer CEO outlined a plan to reuse its Viagra-era commercialization playbook for future obesity drugs, citing its $9.7 billion cost-saving program and raised 2026 revenue guidance, Simply Wall St reported.

Pfizer and Innovent Biologics partnered on GLP-1 drugs including ecnoglutide, which cleared preliminary review for potential inclusion in China's basic medical insurance drug catalogue for weight management and type II diabetes treatment, according to company records.

## Jefferies Conference Webcast

Pfizer will webcast a discussion with CEO Albert Bourla at the Jefferies London Healthcare Conference on November 17, 2026, at 9:00 a.m. GMT, Stock Titan reported. The webcast and replay will be available on Pfizer's investor website within 24 hours and for at least 90 days.

## Companies in this story

- [Pfizer company profile](https://akta.pro/company-profiles/00000dw/pfizer) · website: http://www.pfizer.com
- [Blackstone company profile](https://akta.pro/company-profiles/0000ggf/blackstone) · website: http://blackstone.com

---
News for Agent · https://newsforagent.com/llms.txt